Table 2.
Univariate analyses of TGFBI methylation in non-small cell lung cancer patients
| Variable | Methylation status | P-value | |
| Absent | Present | ||
| Age (mean ± SD) | 57.5 ± 8.4 | 60.0 ± 8.2 | 0.3037 |
| Sex | 0.4900 | ||
| Male | 26 (56.5%) | 20 (43.5%) | |
| Female | 1 (25.0%) | 3 (75.0%) | |
| Pathological stage | 0.8766 | ||
| I | 9 (50.0%) | 9 (50.0%) | |
| II | 6 (50.0%) | 6 (50.0%) | |
| III | 10 (62.5%) | 6 (37.5%) | |
| IV | 2 (50.0%) | 2 (50.0%) | |
| Differentiation | 0.3890 | ||
| Well | 1 (50.0%) | 1 (50.0%) | |
| Moderate | 15 (48.4%) | 16 (51.6%) | |
| Poor | 8 (57.1%) | 6 (42.9%) | |
| Unknown | 3 (100.0%) | 0 (0.0%) | |
| Tumor size (cm) (mean ± SD) | 4.19 ± 2.34 | 4.62 ± 2.62 | 0.6543 |
| Tumor status | 0.2946 | ||
| T1 | 11 (61.1%) | 7 (38.9%) | |
| T2 | 12 (46.2%) | 14 (53.8%) | |
| T3 | 2 (66.7%) | 1 (33.3%) | |
| T4 | 1 (100.0%) | 0 (0.0%) | |
| Tx | 2 (100.0%) | 0 (0.0%) | |
| Metastatic status | 0.6871 | ||
| Primary tumor | 22 (61.1%) | 14 (38.9%) | |
| Lymph node metastasis | 4 (40.0%) | 6 (60.0%) | |
| Distant metastasis | 2 (50.0%) | 2 (50.0%) | |
| Histology | 0.6614 | ||
| Adenocarcinoma | 14 (58.3%) | 10 (41.7%) | |
| Squamous cell carcinoma | 12 (52.2%) | 11 (47.8%) | |